Free Trial
BATS:HELX

Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News

$28.04 +0.89 (+3.27%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Franklin Genomic Advancements ETF (BATS:HELX)

Key Stats

Today's Range
$27.55
$27.55
50-Day Range
$25.72
$28.05
52-Week Range
$23.74
$33.98
Volume
2,058 shs
Average Volume
3,306 shs
Market Capitalization
$11.22 million
Assets Under Management
$11.25 million
Dividend Yield
N/A
Net Expense Ratio
0.50%
Aggregate Rating
Moderate Buy

ETF Overview

Franklin Genomic Advancements ETF Expenses

TypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFs
Management Fee0.50%0.57%0.56%0.57%0.53%
Other Expenses0.00%0.58%0.56%0.48%0.56%
Total Expense0.50%0.74%0.76%0.71%0.73%
Fee Waiver0.00%-0.76%-0.66%-0.46%-0.63%
Net Expense0.50%0.60%0.63%0.64%0.60%
Receive HELX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

HELX ETF News Headlines

Franklin Emerging Markets UCITS ETF (FLXE)
Franklin Ethereum ETF (EZET)
July 4th: 59% dividend from Bitcoin (No Crypto Needed)
I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Yes, you read that right. And no, you don't need to buy any cryptocurrency or trade options... Here's the deal: Our July 4th special includes a FREE report on what I call the "Bitcoin Income Vault."
Franklin U.S. Treasury Bond ETF
See More Headlines

HELX ETF - Frequently Asked Questions

Franklin Genomic Advancements ETF's stock was trading at $28.85 on January 1st, 2025. Since then, HELX shares have decreased by 2.8% and is now trading at $28.0450.

Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), Abiomed (ABMD), Catalent (CTLT), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Net Element (NETE), Novavax (NVAX) and AbbVie (ABBV).

Fund Details

Issuer
Franklin Templeton Investments
Fund Name
Franklin Genomic Advancements ETF
Tax Classification
Regulated Investment Company
Stock Exchange
BATS
Current Symbol
BATS:HELX
Inception Date
2/25/2020
Fund Manager
Matthew J.Moberg, Joyce Lin
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
67

Fund Statistics

Assets Under Management
$11.25 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
Franklin Templeton Services, LLC
Advisor
Franklin Advisers, Inc.
Custodian
State Street Bank and Trust Company
Distributor
Franklin Templeton Distributors, Inc.
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Miscellaneous

Beta
1.05
Creation Unit
50,000
Creation Fee
$200.00
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Top 10 HELX Holdings

HELX Sector Exposure

HELX Industry Exposure


This page (BATS:HELX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners